Aviado · Research
Longevity Daily
Monday, July 27, 2026
Listen
Today's Brief
Today's most important story is a Lancet Public Health analysis of 204 countries showing that humans now spend nearly 11 years in poor health at the end of life — up from 8.8 years in 1990 — a stark reminder that lifespan gains mean little without healthspan. On the supplement front, a Eurofins quality-testing sweep has now flagged two dozen ubiquinol products as dramatically underdosed, making third-party verification essential for anyone taking CoQ10. Metformin's newly uncovered brain-acting mechanism and oral bacteria's emerging role in cognitive decline add two more actionable signals, while our Aviado Research piece rounds out the edition.
10 stories1 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
Metformin's Brain Action: Scientists Uncover a New Mechanism After 60 Years
After six decades in clinical use as a first-line diabetes drug, researchers have identified a previously unknown mechanism by which metformin acts directly on the brain — beyond its well-established role of reducing liver glucose output. The discovery strengthens the case for metformin as a longevity compound and raises important questions about whether its neuroprotective effects extend to people without diabetes. If you're following the TAME trial (Testing Aging in Metformin), this adds meaningful context to what that landmark study is actually measuring.
Read more →Your Mouth May Be Aging Your Brain: Oral Bacteria Linked to Cognitive Decline
Scientists are building a compelling case for treating the mouth as a primary source of body-wide inflammation — one that reaches the brain. When oral bacteria escape into the bloodstream through gum disease or poor dental hygiene, they appear to trigger inflammatory cascades that accelerate both cardiovascular aging and neurodegeneration. The practical takeaway is unusually concrete: your dentist appointment may be doing more for your long-term cognitive health than almost any supplement on your shelf.
Read more →Supplements & Compounds
Two Dozen Ubiquinol Supplements Fail Quality Testing — Is Yours on the List?
A new round of Eurofins independent laboratory testing has identified four more ubiquinol (CoQ10) products containing only a fraction of their labeled active ingredient, bringing the total number of flagged products to 24. If you're taking ubiquinol for mitochondrial support or cardiovascular health, the dose on your label may bear no resemblance to what's actually in the capsule. Third-party certification — NSF, USP, or Informed Sport — is no longer optional when choosing a CoQ10 product.
Read more →On NAD+ Therapy? Here's What You Shouldn't Be Taking With It
High doses of nicotinamide — a form of vitamin B3 and a common NAD+ precursor — have been shown in studies to reduce insulin sensitivity, meaning your body responds less effectively to insulin. This is a significant caution if you're stacking NMN or NR alongside diabetes medications, or if you're monitoring metabolic health. The piece maps out other combinations to watch, including interactions with blood thinners, alcohol, and certain antidepressants.
Read more →Rhonda Patrick's Full Supplement Stack for 2026 — With Brands
This updated breakdown of Dr. Rhonda Patrick's current supplement protocol covers her specific choices and brand preferences for vitamin D + K2, omega-3s, magnesium, sulforaphane, and more — reflecting how her regimen has evolved as the evidence has developed. Patrick is one of the most research-literate practitioners in the longevity space, and tracking how her protocol changes year over year is one of the clearest windows into what the evidence currently supports. Bear in mind: this represents one individual's highly informed choices, not a clinical prescription.
Read more →Research & Papers
We're Living Longer — But Spending Nearly 11 Extra Years Sick. A Lancet Wake-Up Call.
A landmark Lancet Public Health study tracking 204 countries found that global life expectancy rose from 64.6 to 73.8 years between 1990 and 2023 — but healthy life expectancy failed to keep pace. The result: the average person now spends 10.7 years in poor health before death, up from 8.8 years in 1990, a gap that has grown in virtually every region of the world. This reframes the entire longevity mission: the goal is not just to add years to life, but to compress the period of morbidity at the end — and this data makes clear that medicine alone isn't achieving that. For anyone interested in healthspan interventions, this is the benchmark you're working against.
Read more →How the Immune System Ages: A Field-Wide Review of What We Know
This Fight Aging! review synthesizes the current state of research on immunosenescence — covering how the thymus, bone marrow, spleen, and lymphatic system all deteriorate with age, and why that matters well beyond infection risk. As the supply of fresh immune cells declines, dysfunctional and senescent immune cells accumulate, impairing the tissue maintenance functions that keep organs young. For readers tracking senolytics, thymus rejuvenation, or CAR-T longevity therapies, this is a useful map of the problem these interventions are trying to solve.
Read more →Aviado Research: Latest Analysis
Aviado Research's most recent deep-dive covers the latest developments at the intersection of longevity science and clinical evidence. Read the full piece for Aviado's expert perspective on the data.
Read the full Aviado analysis →Lifestyle & Nutrition
The One Food Every Blue Zone Has in Common — and It Costs Almost Nothing
Longevity researcher Dan Buettner, who has spent decades studying the world's longest-lived communities, says beans are the single food that appears consistently across every Blue Zone diet — from lentils in Sardinia and black beans in Costa Rica to soybeans in Okinawa. Long-term observational data associates roughly a half-cup of legumes daily with a meaningful reduction in all-cause mortality, and Buettner notes they are available tinned at any supermarket. It's one of the few longevity recommendations that's both well-supported and extremely cheap to act on.
Read more →Industry & Policy
As Developing Nations Age Fast, Could Longevity Drugs Like Rapamycin Go National First in the Global South?
A Wall Street Journal analysis — picked up by Rapamycin News — highlights a striking policy paradox: countries like Thailand are aging rapidly without the pension systems or healthcare infrastructure to cope, creating unexpected pressure to adopt longevity interventions at a national level. Some observers argue that low-resource governments, unburdened by the cautious regulatory cultures of wealthy nations, could move faster on drugs like rapamycin than the US or EU. It's a speculative but thought-provoking macro frame for anyone watching how longevity medicine scales globally.
Read more →